PHGDH Inhibitor CBR-5884 Inhibits Epithelial Ovarian Cancer Progression Via ROS/Wnt/-Catenin Pathway and Plays a Synergistic Role with PARP Inhibitor Olaparib

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2022 Sep 15

PMID 36105480

Authors

Xiaocui Zhang

Meige Sun

Yisheng Jiao

Bei Lin

Qing Yang

Affiliations

Soon will be listed here.

Abstract

PHGDH attaches importance to serine biosynthesis in cancer cells and maintaining mitochondrial redox homeostasis. However, the role of PHGDH inhibitor CBR-5884 in cell ROS level and its downstream pathways has not been explored in epithelial ovarian cancer. Thus, we investigated the function and possible mechanism of PHGDH inhibitor CBR-5884 on epithelial ovarian cancer in vitro and in vivo. A2780, OVCAR3, and ES-2 were treated with CBR-5884 at different concentrations or different time points. Results showed that CBR-5884 inhibited epithelial ovarian cancer cell proliferation, migration, and invasion and increases cell ROS level. Meanwhile, CBR-5884 exerts antitumor effect through activating ROS/Wnt/-catenin pathway. Besides, CBR-5884 exerts antitumor effect in vivo. What's more, we explored the effect of CBR-5884 with or without PARP inhibitor Olaparib, which showed that the two together had a larger effect. In conclusion, PHGDH inhibitor CBR-5884 inhibits epithelial ovarian cancer proliferation, migration, and invasion through activating ROS/Wnt/-catenin pathway and plays a synergistic role with PARP inhibitor olaparib, which provided a theoretical basis for PHGDH inhibitor CBR-5884 in clinical treatment.

Citing Articles

Glucose Metabolism and Tumor Microenvironment: Mechanistic Insights and Therapeutic Implications.

Andryszkiewicz W, Gasiorowska J, Kubler M, Kublinska K, Palkiewicz A, Wiatkowski A Int J Mol Sci. 2025; 26(5).

PMID: 40076506 PMC: 11900028. DOI: 10.3390/ijms26051879.

Overview of Wnt/β-Catenin Pathway and DNA Damage/Repair in Cancer.

Nadin S, Cuello-Carrion F, Cayado-Gutierrez N, Fanelli M Biology (Basel). 2025; 14(2).

PMID: 40001953 PMC: 11851563. DOI: 10.3390/biology14020185.

PHGDH: a novel therapeutic target in cancer.

Lee C, Hwang Y, Kim M, Park Y, Kim H, Fang S Exp Mol Med. 2024; 56(7):1513-1522.

PMID: 38945960 PMC: 11297271. DOI: 10.1038/s12276-024-01268-1.

ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis.

Gong K, Huang Y, Zheng Y, Hao W, Shi K J Transl Med. 2024; 22(1):192.

PMID: 38383406 PMC: 10880229. DOI: 10.1186/s12967-024-04980-8.

CCT2 prevented β-catenin proteasomal degradation to sustain cancer stem cell traits and promote tumor progression in epithelial ovarian cancer.

Chen J, Hu Q, Zhou C, Jin D Mol Biol Rep. 2024; 51(1):54.

PMID: 38165547 DOI: 10.1007/s11033-023-09047-3.

References

Liu S, Sun Y, Jiang M, Li Y, Tian Y, Xue W . Glyceraldehyde-3-phosphate dehydrogenase promotes liver tumorigenesis by modulating phosphoglycerate dehydrogenase. Hepatology. 2017; 66(2):631-645. DOI: 10.1002/hep.29202. View

Li Q, Qiu J, Yang H, Sun G, Hu Y, Zhu D . Kinesin family member 15 promotes cancer stem cell phenotype and malignancy via reactive oxygen species imbalance in hepatocellular carcinoma. Cancer Lett. 2019; 482:112-125. DOI: 10.1016/j.canlet.2019.11.008. View

Narod S . Can advanced-stage ovarian cancer be cured?. Nat Rev Clin Oncol. 2016; 13(4):255-61. DOI: 10.1038/nrclinonc.2015.224. View

Chen J, Solomides C, Parekh H, Simpkins F, Simpkins H . Cisplatin resistance in human cervical, ovarian and lung cancer cells. Cancer Chemother Pharmacol. 2015; 75(6):1217-27. DOI: 10.1007/s00280-015-2739-2. View

Deng W, Wang Y, Zhao S, Zhang Y, Chen Y, Zhao X . MICAL1 facilitates breast cancer cell proliferation via ROS-sensitive ERK/cyclin D pathway. J Cell Mol Med. 2018; 22(6):3108-3118. PMC: 5980113. DOI: 10.1111/jcmm.13588. View

Wang Y, Jia T, Feng Y, Liu S, Zhang W, Zhang D . Hyperlipidemia Impairs Osseointegration via the ROS/Wnt/β-Catenin Pathway. J Dent Res. 2021; 100(6):658-665. DOI: 10.1177/0022034520983245. View

Zhou H, Lu X, Du C, Zhou Z, Feng J, Liang Z . Cycloacceleration of Reactive Oxygen Species Generation Based on Exceedingly Small Magnetic Iron Oxide Nanoparticles for Tumor Ferroptosis Therapy. Small. 2022; 18(35):e2202705. DOI: 10.1002/smll.202202705. View

Li H, Chen J, Liu J, Lai Y, Huang S, Zheng L . CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism. Exp Cell Res. 2021; 409(1):112892. DOI: 10.1016/j.yexcr.2021.112892. View

Zhang B, Zheng A, Hydbring P, Ambroise G, Ouchida A, Goiny M . PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis. Cell Rep. 2017; 19(11):2289-2303. DOI: 10.1016/j.celrep.2017.05.067. View

10.

Li B, Cao Y, Meng G, Qian L, Xu T, Yan C . Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. EBioMedicine. 2018; 39:239-254. PMC: 6355660. DOI: 10.1016/j.ebiom.2018.11.063. View

11.

Hirata N, Yamada S, Sekino Y, Kanda Y . Tobacco nitrosamine NNK increases ALDH-positive cells via ROS-Wnt signaling pathway in A549 human lung cancer cells. J Toxicol Sci. 2017; 42(2):193-204. DOI: 10.2131/jts.42.193. View

12.

Barreiro-Alonso A, Lamas-Maceiras M, Rodriguez-Belmonte E, Vizoso-Vazquez A, Quindos M, Cerdan M . High Mobility Group B Proteins, Their Partners, and Other Redox Sensors in Ovarian and Prostate Cancer. Oxid Med Cell Longev. 2015; 2016:5845061. PMC: 4670870. DOI: 10.1155/2016/5845061. View

13.

Wang S, Chen M, Chou Y, Ueng Y, Yin P, Yeh T . Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway. Oncotarget. 2016; 7(45):74132-74151. PMC: 5342041. DOI: 10.18632/oncotarget.12356. View

14.

Mullarky E, Lucki N, Zavareh R, Anglin J, Gomes A, Nicolay B . Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proc Natl Acad Sci U S A. 2016; 113(7):1778-83. PMC: 4763784. DOI: 10.1073/pnas.1521548113. View

15.

Wu X, Xia J, Zhang J, Zhu Y, Wu Y, Guo J . Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma. Br J Haematol. 2020; 190(1):52-66. DOI: 10.1111/bjh.16503. View

16.

Fenner A . Kidney cancer: PHGDH is key for targeting HIF in RCC. Nat Rev Urol. 2017; 14(12):702. DOI: 10.1038/nrurol.2017.176. View

17.

Popa M, Fosse V, Kleinmanns K, Bjorge L, McCormack E . Xenograft Models of Ovarian Cancer for Therapy Evaluation. Methods Mol Biol. 2021; 2424:275-293. DOI: 10.1007/978-1-0716-1956-8_18. View

18.

Slade D . PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020; 34(5-6):360-394. PMC: 7050487. DOI: 10.1101/gad.334516.119. View

19.

Moloney J, Cotter T . ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2017; 80:50-64. DOI: 10.1016/j.semcdb.2017.05.023. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View